Senate panel eyes new effort on drug shortages

Sen.RonWyden,D-Ore.,left,andSen.MikeCrapo,R-Idaho,right,walkonCapitolHillin2021.SusanWalsh/APWASHING AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri




focus

author：fashion    Page View：36648

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

  • Irena Melnikova, Ph.D., partner, Pfizer Ventures
  • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
  • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Why Sanofi got shellacked over its spinoff
Next article： How one medical school became remarkably diverse